By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1 DNA Way

South San Francisco  California  94080-4990  U.S.A.
Phone: 650-225-1000 Fax: 650-225-6000

Since 2005, Genentech has been expanding its facilities in Oceanside, about 35 miles north of San Diego. Today, the campus spans 60 acres and includes a multi-product, biotech manufacturing and clinical operations complex with six buildings totaling 500,000 square feet. Upon receiving U.S. Food and Drug Administration licensure in 2007, the Oceanside facility added 90,000 liters of capacity that are now approved for the production of Rituxan and Avastin bulk drug substance.

On the Southern California Coast, halfway between Los Angeles and San Diego, Oceanside is a beautiful beachfront community of roughly 200,000 people. As one of Oceanside’s largest employers, Genentech takes great pride in the impact we have on the community, but also in the impact the community has on our employees.

Please view our company video on YouTube:

Connect with us via Social Media:




Key Statistics

Ownership: Subsidiary

Web Site: Genentech
Employees: 10,000+
Symbol: RHHBY



Company News
Arvinas Inks $300 Million Deal With Genentech (RHHBY) Over Protein Degradation Technology 10/1/2015 6:30:24 AM
Genentech (RHHBY) May Have a $5 Billion MS Blockbuster on Its Hands 9/29/2015 6:31:00 AM
Two Positive Studies Of Genentech (RHHBY)’s Investigational Cancer Immunotherapy Atezolizumab In Specific Type Of Lung Cancer Presented At 2015 European Cancer Congress 9/28/2015 1:49:51 PM
Genentech (RHHBY)'s New Drug Shows Benefits in Phase II Lung, Bladder Cancer Tests 9/28/2015 8:10:05 AM
Genentech (RHHBY)’s ORATORIO Trial Meets Primary Endpoint in Phase III; FDA Data Submission Planned for 2016 9/28/2015 7:51:19 AM
Genentech (RHHBY) Shuttle Drivers Get Wage Increase 9/28/2015 7:39:08 AM
Xenon Pharmaceuticals Inc. Achieves Milestone In Genentech (RHHBY) Collaboration To Discover Novel Pain Targets 9/21/2015 8:09:05 AM
FDA Grants Genentech (RHHBY)’s Alectinib Priority Review For Specific Type Of ALK-Positive Lung Cancer 9/9/2015 11:03:37 AM
Genentech (RHHBY)’s Alectinib Granted Priority Review by the FDA 9/9/2015 6:02:02 AM
Genentech (RHHBY) to Present Data from 15 Oncology Studies at European Cancer Congress 9/8/2015 5:56:17 AM